[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609339":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":45,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Hospital de Alta Complejidad en Red","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants over 18 years of age diagnosed with hereditary transthyretin amyloidosis",null,"Participants with a pathogenic variant of the TTR gene confirmed by genetic testing, whether symptomatic and\u002For with suspected disease progression, as well as asymptomatic carriers of these variants, will be included. Individuals with wild-type TTR amyloidosis will be excluded .",[13],"Other: clinical assessments and complementary examinations",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"clinical assessments and complementary examinations","Evaluation Plan\n\nComprehensive Examination: Complete medical history and physical examination of all body systems, including height and weight measurements.\n\nClinical Parameters: Pulse\u002Fheart rate, respiratory rate, and SpO2 will be monitored. The NYHA classification will be used to assess heart failure if applicable.\n\nNeurological Examination: Includes motor strength testing, sensory testing (pinprick, light touch, temperature, proprioception), deep tendon reflexes, and gait assessment.\n\nElectrocardiogram (ECG): A 12-lead ECG will be performed with the subject at rest for at least 5 minutes in a supine position.\n\n24-hour Holter Monitoring: Conducted in cases of suspected arrhythmias or echocardiographic findings indicating arrhythmias.\n\nColor Dosments and complementary examinations",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Gisela Zanga, MD","CONTACT","+5491156074899","gzanga84@hotmail.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hospital Cuenca Alta de Cañuelas","RECRUITING","Canuelas","Buenos Aires","1814","Argentina","AR",{"type":35,"coordinates":36},"Point",[37,38],-58.76205,-35.05379,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":43,"phoneExt":10,"email":44},"Debora Nadur, MD","+5491139180350","debonadur@hotmail.com",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Gisela Mariel Zanga","PRINCIPAL INVESTIGATOR","100609339","comprehensive-program-for-hereditary-transthyretin-amyloidosis-100609339",false,"NCT07213297","Comprehensive Program for Hereditary Transthyretin Amyloidosis","Inclusion Criteria:\n\n-Participants with a pathogenic variant of the TTR gene (Hereditary Amyloidosis)\n\nExclusion Criteria:\n\n* wild-type TTR amyloidosis","ALL","18 Years",{"count":58,"type":59},20,"ESTIMATED","3 Years","OBSERVATIONAL","The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.",[64,65],"Amyloidosis in Transthyretin (TTR)","Amyloidosis, Familial",[67,68,69],"transthyretin","amyloidosis","comprensive care","2026-03-20",{"date":72,"type":73},"2026-03-24","ACTUAL",{"date":75,"type":73},"2025-11-01",{"date":77,"type":59},"2028-12-01",{"name":5,"class":6},1]